The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
Roberta Ferraldeschi
No relevant relationships to disclose
Rachel Krupa
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Jessica Louw
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Eric Tucker
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Natalee Bales
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Dena Marrinucci
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Penelope Flohr
No relevant relationships to disclose
Ines Figueiredo
No relevant relationships to disclose
David Lorente
No relevant relationships to disclose
Ryan Dittamore
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Johann Sebastian De Bono
Consultant or Advisory Role - Genentech/Roche
Research Funding - Genentech; Ventana
Other Remuneration - Genentech/Roche
Gerhardt Attard
Consultant or Advisory Role - Roche/Ventana; Veridex
Research Funding - Genentech; Ventana
Other Remuneration - Roche/Ventana; Veridex